Endocrine Abstracts

Introduction: Acromegaly is characterized by elevated levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), most often due to a pituitary tumor. Persistent high levels of these hormones lead to a constellation of signs and symptoms and systemic complications associated with increased mortality. A potential association between acromegaly and cancer has been hypothesized regarding colorectal, thyroid, and prostate cancers, but there are few or no descriptions f...

Background: Acromegaly is a rare disorder caused by hypersecretion of growth-hormone (GH) and insulin-like growth factor (IGF-1), the underlying lesion being most frequently a pituitary adenoma. This disease is associated with a higher risk of malignancy. We describe the clinical and biochemical particularities in a series of patients with acromegaly and papillary thyroid carcinoma (PTC).Case study: Out of 311 acromegalic patients, five cases that associ...

Introduction: Acromegaly is a rare, chronic endocrinopathy, that results from persistent hypersecretion of growth hormone (GH) and consequently of insulin-like growth factor 1 (IGF1). It is well known that GH excess has multisystemic effects throughout the body, but its interaction with the immune system has only been suggested in the last few decades. This prompted us to explore the frequency of autoimmune disorders in a retrospective acromegaly cohort....

Background: Neuroendocrine tumors (NETs) are relatively uncommon, accounting for 10 to 14 percent of all neuroendocrine neoplasms. Twelve percent to 22% of patiens are metastatic at presentation. The most frequent primary sites are the gastrointestinal tract (62–67%) and the lung (22–27%).Case presentation: We report the case of a 36-year-old female patient diagnosed with metastatic disease, with liver, lung and lymph nodes metastasis with un...

Background: Immune checkpoint inhibitors (ICIs) are a novel group of drugs, used for treatment of various types of malignancies. The receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) or its ligand (PDL-1) are targeted by those inhibitors. They are associated with immune-related adverse events (irAEs). Endocrinopathies are the most frequent irAEs with a prevalence of approximately 10%. Case study: We retrospect...